Goldman Sachs analyst Andrea Tan initiated coverage of Verve Therapeutics with a Sell rating and $13 price target. The FDA’s recent investigational new drug hold, which requests additional data to evaluate the safety risk, presents a near-term overhang, Tan tells investors in a research note. In the long-term, the analyst sees significant risk to Verve’s commercial opportunity as her key opinion leader discussions "highlight hesitancy around a novel gene editing modality given the uncertain benefit/risk profile."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERV:
- Verve Plunges After FDA Clinical Hold
- Verve FDA request ‘provides fodder for both bulls and bears,’ says Stifel
- Verve Therapeutics receives information from FDA regarding clinical hold
- Beam hold being lifted ‘encouraging’ for Verve Therapeutics, says Guggenheim
- Verve Therapeutics to Participate in Upcoming Investor Conferences
